Hormone replacement formulation

• US 6,911,438 B2
• Filed: 09/12/2001
• Issued: 06/28/2005
• Est. Priority Date: 09/12/2001
• Status: Active Grant

• Current Assignee: Jonathan V. Wright
• Original Assignee: Jonathan V. Wright
• Inventors: Wright, Jonathan V.
• Primary Examiner(s): Wang, Shengjun
• Application Number:
  US09/951,489
• Publication Number:
  US 20030050287A1
• Time in Patent Office: 1,385 Days
• Field of Search: 514/170, 514/171, 514/182, 514/179
• US Class Current: 514/170
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/525 Isoalloxazines, e.g. riboflavins, vitamin B2
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 33/04 Sulfur, selenium or tellurium; Compounds thereof
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The formulation comprises a combination of three estrogens and selected amount of other elements. The three estrogens include 2-hydroxyestrone, 17-beta estradiol, and estriol. The amount of 17-beta estradiol is substantially less than the amounts of 2-hydroxyestrone and estriol, both which are approximately equal in amount. The amounts of pyridoxine, folic acid, selenium and cobalt are therapeutically effective amounts.

Claims

1. An estrogen formulation for use in hormone replacement therapy, comprising:

a combination of three estrogens, the combination including an amount of 2-hydroxyestrone, an amount of 17-beta estradiol, and an amount of estriol, wherein the amounts of 2-hydroxyestrone and estriol are approximately equal and wherein each comprise approximately 35%-45% by weight of the three estrogens, and wherein the 17-beta estradiol comprises the remainder of the three estrogen combination.

2. A formulation of claim 1, further including a selected amount of cobalt.

3. A formulation of claim 1, further including a selected amount of selenium.

4. a formulation of claim 2, further including a selected amount of selenium.

5. A formulation of claim 4, further including selected amounts of pyridoxine and folic acid.

6. An article of claim 5, wherein the formulation comprises 1000-1125 micrograms of 2-hydroxyestrone, 200-500 micrograms of 17-beta-estradiol, 1000-1125 micrograms of estriol, 20 milligrams of pyridoxine, 400-800 micrograms of folic acid;

200-300 micrograms of cobalt; and

200-300 micrograms of selenium.

7. An estrogen formulation for use in hormone replacement therapy, comprising:

a combination of two estrogens, the combination including an amount of 2-hydroxyestrone and an amount of 17-beta estradiol, wherein the formulation comprises 80-90% of 2-hydroxyestrone and 10-20% of 17-beta estradiol.